Last reviewed · How we verify

Ferring Pharmaceuticals — Portfolio Competitive Intelligence Brief

Ferring Pharmaceuticals (Private) pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Private (Private) 5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Menopur MENOTROPINS marketed Other 2013-01-01
Firmagon degarelix marketed Gonadotropin Releasing Hormone Receptor Antagonist Gonadotropin-releasing hormone receptor Oncology 2008-01-01
Acthrel corticorelin ovine marketed Nephrology 1996-01-01
Endometrin progesterone marketed Progesterone [EPC] Corticosteroid-binding globulin, Sodium/nucleoside cotransporter 1, Cation channel sperm-associated protein 1 Women's Health
Choriogonadotropin chorionic gonadotrophin marketed Metabolic

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. AbbVie · 1 shared drug class
  3. Dunamenti REK Istenhegyi IVF Center · 1 shared drug class
  4. Merck KGaA · 1 shared drug class
  5. Organon Usa Organon · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ferring Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Ferring Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ferring. Accessed 2026-05-13.

Related